CGRP receptor inhibitors already showed high efficacy in the treatment of migraine, which is presumably caused via CALCA- or CALCB-mediated vasodilatation in the vicinity of the trigeminal ganglia—the only normal tissue type with physiologically high CALCB expression levels found in our analyses. The gene discussed is CALCA; the disease is migraine disorder.